Skip to main content

FDA Approvals

Kimmtrak, a Bispecific CD3 T-Cell Engager, First FDA-Approved Drug for Unresectable or Metastatic Uveal Melanoma

FDA Approved Fyarro for Malignant Perivascular Epithelioid-Cell Tumor

Oral Scemblix FDA Approved for Patients with Ph-Positive Chronic Myeloid Leukemia

Verzenio with Endocrine Therapy FDA Approved for Adjuvant Treatment of Early Breast Cancer

Tecartus FDA Approved for Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia

Brukinsa Approved for Marginal-Zone Lymphoma and for Waldenström’s Macroglobulinemia

Nivolumab First Immunotherapy Approved for Adjuvant Treatment of Urothelial Carcinoma

Jemperli Another Therapy Approved for Patients with dMMR Recurrent or Advanced Solid Tumors

Cabometyx Receives FDA Approval for Differentiated Thyroid Cancer

Exkivity Novel Oral Targeted Therapy Approved for Metastatic NSCLC with EGFR Exon 20 Insertion Mutations

Page 7 of 20
Results 61 - 70 of 200